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Subchondral bone may contribute to knee osteoarthritis (OA) pain. Nerve growth factor 39 
(NGF) can stimulate nerve growth through TrkA. We aimed to identify how sensory nerve 40 
growth at the osteochondral junction in human and rat knees associates with OA pain. 41 
Methods 42 
Eleven symptomatic chondropathy cases were selected from people undergoing total knee 43 
replacement for OA. Twelve asymptomatic chondropathy cases who had not presented 44 
with knee pain were selected post-mortem. OA was induced in rat knees by meniscal 45 
transection (MNX) and sham-operated rats were used a  controls. Twice-daily oral doses 46 
(30 mg/kg) of TrkA inhibitor (AR786) or vehicle wer administered from before and up to 47 
28 days after OA induction. Joints were analysed for macroscopic appearances of articular 48 
surfaces, OA histopathology and calcitonin gene-related peptide-immunoreactive 49 
(CGRP-IR) sensory nerves in medial tibial plateaux, and rats were assessed for pain 50 
behaviors. 51 
Results 52 
The percentage of osteochondral channels containing CGRP-IR nerves in symptomatic 53 
chondropathy was higher than in asymptomatic chondropathy (difference: 2.5% [95% CI: 54 
1.1-3.7]), and in MNX- than in sham-operated rat knees (difference: 7.8% [95%CI: 55 
1.7-15.0]). Osteochondral CGRP-IR innervation was significantly associated with pain 56 
behavior in rats. Treatment with AR786 prevented the increase in CGRP-IR nerves in 57 
osteochondral channels and reduced pain behavior in MNX-operated rats. Structural OA 58 
was not significantly affected by AR786 treatment. 59 
Conclusions 60 
CGRP-IR sensory nerves within osteochondral channels ar  associated with pain in human 61 
and rat knee OA. Reduced pathological innervation of the osteochondral junction 62 











Introduction  74 
Knee osteoarthritis (OA) is a common cause of pain and disability. Pain is the most 75 
common reason sufferers seek medical help. Recent human studies showed that 76 
subchondral bone marrow lesions (BMLs) detected on magnetic resonance imaging (MRI) 77 
in knee OA are associated with pain1-3. Microarray analysis of subchondral BMLs in OA 78 
demonstrated upregulation of genes implicated in neurogenesis, osteochondral turnover 79 
and inflammation that might contribute to OA pain4.  80 
Nerve growth factor (NGF) is localized in subchondral bone of the human tibial plateau5, 81 
cartilage5 and synovium6 in OA and rheumatoid arthritis and NGF plays a keyrole in the 82 
generation of knee OA pain through actions on its hgh affinity receptor tropomyosin 83 
receptor kinase A (TrkA). The NGF/TrkA pathway has emerged as an important 84 
therapeutic target for human OA pain. Antibodies that block NGF reduce pain in human 85 
and rodent knee OA7, and selective, allosteric inhibitors of TrkA such as AR786 can inhibit 86 
pain in rat OA models8, and in human OA9, although a randomized controlled trial did not 87 
suggest analgesic effects of TrkA inhibition in knee OA10.  88 
NGF/TrkA pathway inhibitors reduce pain through direct actions on peripheral sensory 89 
nerves. TrkA is expressed by peptidergic nerves which contain the neuropeptide calcitonin 90 
gene-related peptide (CGRP)11. CGRP-immunoreactive (IR) sensory nerves contribute to 91 
OA pain12,13. NGF increases pain by sensitizing nerves14. NGF can also stimulate sensory 92 
nerve growth15,16. Sensory nerve densities have been associated with pain in nonhealed 93 
bone fractures17, aging bone18 and breast pain19. However it is unclear whether sensory 94 
nerve growth contributes to OA pain and whether NGF/TrkA pathway inhibitors are 95 
effective against pathological sensory innervation in OA. In people with OA, CGRP-IR 96 
sensory nerves are colocalized with NGF within ostechondral channels5, and increased 97 
NGF expression in osteochondral channels was associated with symptomatic human knee 98 
OA20. In this study, CGRP-like immunoreactivity was used as a well-established marker of 99 
unmyelinated sensory nerves to confirm innervation at the osteochondral junction. 100 
The first objective of this study was to determine f CGRP-IR sensory nerves at the 101 
osteochondral junction are associated with OA pain in humans by comparing cases with 102 
similar OA structural change but with or without symptoms. One group had sought help for 103 
knee pain and undergone total knee replacement (TKR) surgery (symptomatic 104 
chondropathy), while the other group had not sought help for knee pain but had died from 105 
an unrelated illness (asymptomatic chondropathy). Our second objective was to identify 106 
the effects of blocking NGF activity by inhibiting TrkA on any OA-associated increase of 107 
CGRP-IR sensory nerves and pain behavior in ats with surgically-induced OA. We 108 
hypothesise that lower numbers of CGRP-IR sensory ne ves within osteochondral channels, 109 
due either to pathological phenotype or TrkA inhibition, is associated with less OA pain. 110 
 111 
Material and Methods 112 
Human tissues 113 
Eleven symptomatic chondropathy cases were selected from people who had presented 114 
with severe knee pain and had undergone TKR for OA. Twelve asymptomatic 115 
chondropathy cases who had not presented with knee pain and 11 non-arthritic control 116 
cases who had macroscopically normal articular cartilage or only mild chondropathy were 117 
selected post-mortem (PM). One knee joint from each donor was included. All 118 
asymptomatic chondropathy cases had not sought medical attention for knee pain during 119 
the last year and are highly likely to have experienced less pain than the symptomatic 120 
chondropathy cases. Human tissues were selected according to predefined criteria from a 121 
human Joint Tissue Repository held by the University of Nottingham containing donations 122 
from >2,500 cases at arthroplasty and >400 cases collected post mortem 21. Informed 123 
consent was obtained from TKR cases, or from the next of kin of PM cases. Protocols were 124 
approved by Nottingham 1 Research Ethics Committee 05/Q2403/24 and Derby Research 125 
Ethics Committee 1 11/H0405/2. Symptomatic chondropathy samples were from people 126 
fulfilling American College of Rheumatology classification criteria for OA 22 at the time of 127 
TKR. 128 
Human sample processing 129 
Formalin-fixed coronal sections of the middle third of medial tibial plateaux - MTP (key 130 
weight-bearing area characteristically affected by OA) were decalcified in 10% 131 
ethylenediaminetetraacetic acid (EDTA) in 10mM Tris buffer (pH 6.95, 4°C) prior to wax 132 
embedding. Samples used for CGRP-IR nerves staining were fixed by the method of 133 
Zamboni23 (Supplementary text). Zamboni’s fixed tissues were decalcified, then immersed 134 
and frozen at an optimal cutting temperature and stored at 80°C. 135 
Macroscopic chondropathy score and radiographic OA severity score  136 
Following tissue harvesting, articular surfaces of the MTP were evaluated on the extent 137 
and severity of loss of surface integrity by a single assessor24. Articular surface defects 138 
were graded 0 [normal], 1 [swelling and softening], 2 [superficial fibrillation], 3 [deep 139 
fibrillation] and 4 [subchondral bone exposure]. The proportion of articular surface area 140 
corresponding to each grade was allocated to each severity grade to calculate a 141 
macroscopic chondropathy score;  142 
Macroscopic chondropathy score (0-100) = (Grade 1 x 0.14) + (Grade 2 x 0.34) + (Grade 3 143 
x 0.65) + Grade 424.  144 
Radiographic OA severity scores were derived using preoperative postero-anterior knee 145 
radiographs as previously described24. An atlas of line drawings of the knee joint was used 146 
to grade medial and lateral joint space narrowing ad osteophytes25. Scores for 147 
tibiofemoral joint space narrowing (0–6) and osteophytes (0–12) were summed to provide 148 
a total radiographic OA severity score (0–18)24. 149 
Human histology and grading 150 
Tibial plateaux sections (5µm) were stained with H&E, or Safranin-O and fast green. OA 151 
articular cartilage changes were graded using the Mankin scoring system26 (Supplementary 152 
text). Subchondral bone marrow replacement was defined as replacement of bone marrow 153 
fat spaces with fibrovascular tissue, and assessed a  ither present or absent. Section width 154 
was measured by a digital electronic caliper (Mitutoyo, UK), and densities were calculated 155 
of osteochondral channels per mm in subchondral bone, calcified cartilage and 156 
non-calcified cartilage, and of channels breaching tidemark. 157 
Immunohistochemistry and quantification of CGRP-IR nerve 158 
Tibial plateaux sections (20µm) were blocked with 3% bovine serum albumin (BSA) for 159 
1h at room temperature. The sections incubated in mouse anti-CGRP antibody (1:300 160 
TA309091; Acris Antibodies, Herford, Germany) were diluted in goat blocking serum 161 
overnight in a humid chamber at 4°C. The next day, secondary detection was performed 162 
with goat anti-mouse IgG conjugated with Alexa 488 (1:100 A32723; ThermoFisher 163 
scientific, Mississippi, USA) for CGRP for 2h at room temperature. Before, between, and 164 
after each incubation step, the sections were washed t ree times for 5min in PBS. 165 
CGRP-IR sensory nerves were measured as a proportion (%) of osteochondral channels in 166 
each case that displayed CGRP-IR sensory nerves. One section per each knee joint was 167 
used for analysis of CGRP-IR nerves. 168 
Animals and OA induction 169 
Male Sprague-Dawley rat knee joints (Charles River, K nt, UK), n=30, were collected for 170 
this study from our previous experiment8. The rats were used in accordance with UK Home 171 
Office regulations and followed the guidelines of the International Association for the 172 
Study of Pain. Rats weighing 200–250 g were anaesthetized briefly with isoflurane (2% in 173 
O2) and underwent transection of the medial meniscus (MNX; n=20)27. Non-osteoarthritic 174 
(Sham-operated; n=10) rats were used as controls. Rats were randomized to 3 groups 175 
(sham plus vehicle, MNX plus vehicle and MNX plus AR786) using a computer program, 176 
and mixed within cages. Data presented in this paper extend behavioural data and 177 
macroscopic chondropathy scores that have been reported previously from these rats8. All 178 
outcome measurements were carried out by an experimenter blinded to randomized 179 
treatments. 180 
TrkA inhibitor (AR786) administration 181 
AR786 (Array Biopharma, Boulder, Colorado, USA) was administered in a preventive 182 
protocol based on previous data28,29. Oral doses (30 mg/kg) of AR786 or vehicle (5% 183 
Gelucire 50/13) were administered 1h prior to and 8h following OA induction, and twice 184 
daily until the end of the study (28 days after OA induction).  185 
Rat knee joint pathology and quantification of CGRP-IR nerve 186 
Rats were sacrificed by an overdose of pentobarbital (intraperitoneal) (day 28). Macroscopic 187 
chondropathy scores based on the Guingamp classification30 have been previously published8. For 188 
the current report, histological assessment of cartilage and subchondral bone including osteophytes 189 
in medial tibial plateaux was undertaken based on the Osteoarthritis Research Society 190 
International recommendations31. Subchondral bone marrow replacement by fibrovascular 191 
tissue and osteochondral channel density were assessed in the same way as human samples. 192 
Immunohistochemistry and quantification of CGRP-IR nerve fibers in osteochondral 193 
channels in medial tibial plateaux were carried out in the same way as human samples. 194 
Width of the entire medial proximal tibial epiphysis was measured by a digital caliper and 195 
CGRP-IR nerve density per mm in the bone marrow space was calculated. Two sections 196 
containing weight-bearing area characteristically affected by OA per each knee joint were 197 
used for analysis of CGRP-IR nerves. 198 
Behavioral measurements of OA pain 199 
Pain behavior was assessed as weight-bearing asymmetry and as paw withdrawal threshold 200 
to punctate stimulation of the hind-paw. Baseline measurements were obtained 201 
immediately prior to intra-articular injection or surgery (day 0) and every 2–4 days from 202 
day 3 onwards to day 28 and have been previously reported8 . Weight-bearing asymmetry 203 
was assessed as percent difference in weight distribution between hind-limbs32. 204 
Image analysis 205 
All human and rat histological scoring and quantificat on of CGRP-IR nerve fibers were 206 
undertaken by a single observer (KA) who was blinded to the diagnostic group, using a 207 
Zeiss Axioscop-50 microscope (Carl Zeiss, Welwyn Garden City, UK).  208 
Statistical analysis 209 
Statistical analyses were performed with JMP, Version 10 (SAS Ins. Cary, NC), IBM SPSS 210 
version 26.0 software and IBM SPSS Bootstrapping (IBM Corp. Armonk, NY, USA). Data 211 
of age, gender, radiographic OA score, macroscopic chondropathy score, OA 212 
histopathology, CGRP sensory nerve and pain behaviours were analyzed using 213 
Kruskal-Wallis tests followed by post hoc Dunn’s comparisons. Estimates of mean 214 
differences of CGRP-IR nerve between groups with 95% confidence interval (CI) were 215 
derived from 2000 bootstrap resampling. Logistic regression was performed to adjust for 216 
age. Spearman’s rank correlation (r) assessed associ tions between pain behaviors and 217 
CGRP-IR nerve densities, macroscopic chondropathy score and OA istological changes in 218 
MNX plus vehicle and MNX plus AR786 models (n=20). The 95% CIs for Spearman's 219 
correlation were derived from 2000 bootstrap resampling. Bias-corrected and accelerated 220 




Patient characteristics and joint pathology 225 
Demographics and sample details of cases selected for this study are shown in Table 1. The 226 
asymptomatic chondropathy group was older than the non-arthritic control and 227 
symptomatic chondropathy groups. As expected from our selection criteria, 228 
macroscopic chondropathy scores were similar in asympto atic and symptomatic 229 
chondropathy groups; and both were higher than in no -arthritic controls. Histological 230 
chondropathy scores were higher in chondropathy cases than in non-arthritic controls 231 
(Table 1 and Figure 1 A, B, C). Channels were present at the osteochondral junction in 232 
each group (Figure 1, D). Increased numbers of osteochondral channels breaching the 233 
tidemark (Figure 1 E), and the percentage of cases with subchondral bone marrow 234 
replacement by fibrovascular tissue did not reach statistical significance in chondropathy 235 
groups compared to non-arthritic controls (Table 1). 236 
CGRP-IR sensory nerve fibers in human medial tibial plateaux 237 
CGRP-IR nerve profiles were localized to osteochondral channels and subchondral bone 238 
marrow spaces (Figure 1 F, G, H). The percentage of osteochondral channels containing 239 
CGRP-IR sensory nerves did not significantly differ between chondropathy and 240 
non-arthritic control groups (median percentages (interquartile range (IQR)) of 241 
non-arthritic control, asymptomatic and symptomatic chondropathy were 1.2 (0, 2.9), 0 (0, 242 
1.9) and 3.6 (2.5, 4.7)) (Figure 2). Bootstrap estima es of mean differences between 243 
asymptomatic or symptomatic chondropathy and non-arthritic control were 0.8% [95% CI: 244 
-0.6 to 2.4%] and 1.3% [95%CI: -0.4 to 2.9%], respectiv ly. The percentage of 245 
osteochondral channels containing CGRP-IR sensory nerves in the symptomatic 246 
chondropathy group was higher than in asymptomatic chondropathy group and this 247 
difference remained significant after adjusting forage (aOR=3.9 [95% CI: 1.5 to 31.3], 248 
p=0.01) (Figure 2). The bootstrap estimate of mean difference between symptomatic and 249 
asymptomatic chondropathy was 2.5% [95% CI: 1.1 to 3.7%]. 250 
MNX-induced OA and pain behavior in rats 251 
New data presented here extend previously published macroscopic chondropathy scores, 252 
paw withdrawal thresholds and weight-bearing asymmetry data from these experiments.8 253 
MNX surgery was associated with a greater OA structural change than was sham surgery 254 
(Table 2 and Figure 3A, B, C). Subchondral bone marrow eplacement by fibrovascular 255 
tissue was observed in MNX- but not in sham-operated rats. Numbers of osteochondral 256 
channels did not differ between groups, and were not altered by AR786 treatment (Table 2 257 
and Figure 3D, E, F, C). Asymmetric weight distribut on and reduced paw withdrawal 258 
thresholds were more severe in MNX-operated rats treated with vehicle than in 259 
sham-operated rats at day 28 after surgery, and AR786 reversed the OA-induced pain 260 
behavior (Table 2). 261 
CGRP-IR nerve fibers in rat knee joints 262 
CGRP-IR nerve profiles were localized to osteochondral channels and subchondral bone 263 
marrow spaces in rat knee joints (Figure 3G, H, K). The percentage of osteochondral 264 
channels containing CGRP-IR sensory nerves was higher in MNX-operated knees from 265 
rats treated with vehicle than in sham-operated knees (median percentages (IQR) of sham 266 
plus vehicle and MNX plus vehicle were 2.8 (0.5, 7.4) and 10 (8, 13.7)) (Figure 4A). The 267 
bootstrap estimate of mean difference between sham plus vehicle and MNX plus vehicle 268 
was 7.8% [95% CI: 1.7 to 15.0%]. Treatment with AR786 prevented this increase (Figure 269 
4A and Figure 3G, H, I, J). The bootstrap estimate of mean difference between MNX plus 270 
vehicle and MNX plus AR786 groups was 7.7% [95% CI:2.5 to 14.4%]. CGRP-IR 271 
sensory nerve density in subchondral bone marrow spaces did not differ between groups 272 
(Figure 4B). The percentage of osteochondral channels containing CGRP-IR sensory 273 
nerves in knees from rats 28 days after MNX surgery, treated with vehicle or AR786, was 274 
significantly associated with weight-bearing asymmetry (Spearman’s r=0.50 [95% CI: 0.07 275 
to 0.77], p=0.04), and with paw withdrawal threshold (Spearman’s r=-0.55 [95% CI: -0.82 276 
to -0.08], p=0.02). 277 
 278 
Discussion 279 
We have identified CGRP-IR sensory nerves within oste chondral channels, associated 280 
with symptoms in human knee OA and pain behaviour in MNX-induced rat knee OA. 281 
These new data support the view that CGRP-IR sensory nerves invade the osteochondral 282 
channels from bone marrow spaces in joints with OA cartilage damage. In rats, blocking 283 
NGF activity by inhibiting TrkA prevented the OA-induced growth of CGRP-IR sensory 284 
nerves in osteochondral channels. This was associated with, and might contribute to, 285 
reduced pain behaviour. Our findings support the hypothesis that NGF-induced growth of 286 
sensory nerves at the osteochondral junction might con ribute to chronic pain in knee OA. 287 
In our previous studies on human tissues, we showed NGF-like immunoreactivity in 288 
multinucleate osteoclasts adherent to bone, steochondral channels and synovium (but not 289 
mRNA expression) was associated with OA pain in human OA20,6,33. In the mouse OA 290 
model induced by destabilization of the medial meniscus, increased NGF messenger RNA 291 
in knee joints was also associated with pain behavior34. Increased NGF expression by 292 
osteoclasts might induce the invasion by CGRP-IR sensory nerves into osteochondral 293 
channels. Indeed, nerve fibers are increased in chanels under areas of most damaged 294 
articular cartilage in osteoarthritic mouse knees35, and chondrocytes produce higher NGF 295 
levels in more severely damaged cartilage in human OA36,37,38 and in surgically-induced 296 
mouse knee OA39. However, chondrocyte-derived NGF was not significantly associated 297 
with pain in late-stage OA20. These findings suggest a more important contribution to the 298 
generation of pain from NGF in osteochondral channels and synovium than from 299 
chondrocytes, particularly in late-stage OA. Here w demonstrate that inhibition of the 300 
NGF/TrkA pathway with a specific TrkA inhibitor reduced osteochondral innervation in 301 
the rat. These data extend previous findings that NGF-blocking antibodies can reduce 302 
pathological sensory innervation in bone40 or skin41, to show similar effects of TrkA 303 
inhibition in osteochondral channels. NGF pathway inhibition did not, however, have 304 
detectable effects on mature sensory innervation, csistent with a lack of effect on mature 305 
innervation in other tissues from NGF-blockade42. Subchondral bone marrow lesions 306 
detected by MRI have been associated with OA pain1-3. We speculate that sensitization of 307 
pre-existing nerves in subchondral bone marrow lesions might contribute to OA pain, and 308 
that generation of neurotrophic factors by BMLs4 might contribute to osteochondral 309 
channel innervation. 310 
Nerve growth into articular cartilage occurs within vascular channels. Penetration of 311 
channels into non-calcified articular cartilage has been associated previously with OA 312 
disease, whereas total osteochondral channel densities in calcified and non-calcified 313 
cartilage differ little between OA and non-arthritic joints5. We found that CGRP-IR sensory 314 
nerve densities within osteochondral channels (but not osteochondral channel densities per 315 
se) were higher in symptomatic than in asymptomatic chondropathy. Also, channel 316 
innervation was significantly associated with weight-bearing asymmetry and paw 317 
withdrawal threshold in MNX-induced rat knee OA. These data suggest that rather than an 318 
increase in osteochondral channel densities, increased innervation contributes to OA pain. 319 
Increased NGF expression in osteochondral channels associated with symptomatic knee 320 
OA20, might further contribute to OA pain by sensitizing these osteochondral nerves. 321 
 As previously reported8, blocking NGF activity by oral administration of the specific 322 
TrkA inhibitor AR786 prevented OA-associated pain behaviours in these rats. Inhibiting 323 
the NGF/TrkA pathway reduces peripheral sensitization43,44. We now also show that 324 
AR786 administration prevented the increase in CGRP-IR nerves within osteochondral 325 
channels that otherwise follows OA induction by MNX surgery, and that lower CGRP-IR 326 
nerve densities were significantly associated with less OA-induced pain behavior. 327 
OA is a multi-tissue disease involving many molecular mediators. Our cross sectional 328 
data from humans, and interventional studies in rats, suggest a contribution of NGF 329 
pathway-induced osteochondral innervation to OA pain. Further research should 330 
investigate whether osteochondral innervation might be a predominant cause of pain in 331 
some patients, and its relative importance compared to other pain mechanisms. CGRP-IR 332 
sensory nerves have also been localized to osteoarthritic synovium45,46, possibly in higher 333 
densities than in asymptomatic knees47, particularly in joint compartments displaying 334 
increased sensitivity45. Synovitis has also been associated with OA knee pain, both in 335 
humans6 and in the MNX-induced rat model48. However, we previously showed that 336 
AR786 did not significantly reduce either knee swelling or synovitis in rats with 337 
MNX-induced OA, and synovitis scores were not signif cantly associated with pain 338 
behaviors8. Other aspects of osteochondral pathology in OA might additionally contribute 339 
to OA pain. Loss of osteochondral integrity might increase osteochondral permeability, 340 
exposing subchondral nerves to chemical mediators fr m the cartilage or synovium and 341 
mechanical injury49. Osteoclast activity may also increase pain both by sensitizing 342 
osteochondral nerves and by increasing structural pathology50. Furthermore, NGF both 343 
influences nerve growth, as indicated by our findings, and quickly induces sensitization of 344 
peripheral nerves by multiple signalling pathways14. The rapid onset of analgesia 345 
associated with NGF blockade15 or TrkA inhibition is likely attributable to reduced 346 
peripheral sensitization, rather than to reduced nerve growth, which is a slow process 347 
occuring over a period of weeks51. However, our data indicate that osteochondral 348 
innervation might contribute to OA pain, and suggest that nerve growth might be a key 349 
target for structural disease modification in OA. Other approaches for structural disease 350 
modification in OA have been largely unsuccessful, in part due to the prolonged treatment 351 
required to demonstrate clinically important structural modification, and a lack of 352 
symptomatic benefit. Targeting aspects of OA structural pathology such as aberrant 353 
osteochondral innervation with treatments that also more immediately reduce pain is an 354 
attractive proposition. 355 
Limitations 356 
Quantification of nerves is limited by sensitivity of the immunohistochemical method, and 357 
by the challenge of detecting changes in nerve density i  a tissue which normally contains 358 
nerves. CGRP-IR was used as a well-established marker of unmyelinated sensory nerves 359 
which express TrkA11. Half of neurons innervating the subchondral bone expressed CGRP 360 
and TrkA in normal rat knees, whereas all were isolectin B4-negative52. Sensitivity of 361 
CGRP to detect subchondral sensory nerves might be even higher in OA53. It is unclear 362 
whether CGRP is itself important for OA pain, and, unlike experience with NGF-blocking 363 
antibodies, an RCT of CGRP receptor blockade did not reveal clinically important benefit 364 
for OA pain54. However, different results might have been obtained using other neuronal 365 
markers, and we do not exclude biologically important changes in innervation in tissue 366 
compartments additional to osteochondral channels. We used non-parametric statistical 367 
methods in order to optimize validity depite inclusion of an outlying value for channel 368 
innervation in our per protocol analysis. Future research should seek to confirm our present 369 
findings. 370 
Characteristics other than osteochondral innervation, s me unmeasured, might explain 371 
symptomatic and asymptomatic chondropathy classificat on. However, the groups had 372 
similar chondropathy scores and OA histopathology. Ageing might also influence sensory 373 
innervation in mice35,55, although differences in osteochondral innervation in our study 374 
persisted after adjustment for age. Some people in our `asymptomatic’ chondropathy group 375 
might have experienced chronic knee pain without their relatives knowing. However, all 376 
people undertaking TKR report severe knee pain, and it is highly likely that people who 377 
have not undergone surgery have less knee pain than those who do. Samples were from the 378 
mid-coronal section of the medial tibial plateau, a key weight-bearing area with the 379 
greatest amount of cartilage loss, but findings could differ for other joint regions such as 380 
femoral condyles. We here focused on NGF at the ostochondral junction, and further 381 
systematic studies of other molecules and in other articular tissues might reveal additional 382 
pathways contributing to OA pain. 383 
Conclusions 384 
Our data indicate a possible role of osteochondral innervation and TrkA in structural 385 
pathology which contributes to OA pain. Previous attempts at structural disease 386 
modification in OA have focused on radiographic features such as joint space narrowing 387 
and osteophytosis, features which are only weakly associated with OA pain severity56. 388 
Osteochondral innervation might be a key structural ch nge that contributes to human and 389 
rat OA pain. Most analgesic drugs alter sensory nerve function rather than structure. 390 
Inhibiting pathological nerve growth in osteochondral channels may reduce chronic OA 391 
pain and herald a step change for structural pain modification. 392 
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     Figure 1: Histopathologic features in cartilage and subchondral bone from humans 
A; non-arthritic control. B; Asymptomatic chondropathy. C; Symptomatic chondropathy 
Osteochondral channels were found in the subchondral bone plate in sections from 
non-arthritic control cases (D). Osteochondral channels breaching the tidemark and 
entering non-calcified cartilage in sections from symptomatic chondropathy cases (E). 
CGRP-IR nerves were found in osteochondral channels under the areas of damaged 
cartilage (asterisk) in sections from symptomatic chondropathy cases (white arrow head) (F, 
G). CGRP-IR sensory nerves (arrow) were found in boe marrow space (arrow) (H). (I) 
explains where these images are located within the kne  joint. Black arrow heads indicate 
tide mark. CGRP-IR; calcitonin gene-related peptide-immunoreactive. Scale bars = 100 
µm 
 
Figure 2: Percentage of osteochondral channels containing CGRP-IR sensory nerves 
in non-arthritic control, symptomatic and asymptomatic chondropathy cases. 
Scatterplots illustrate the differences among non-arthritic control, symptomatic and 
asymptomatic chondropathy cases. Lines represent medians and IQR. Data were 
analysed using Kruskal-Wallis test followed by post hoc Dunn’s comparison. 
*p=0.007 versus asymptomatic chondropathy.  
 
Figure 3: Histopathologic features in cartilage and subchondral bone from rats 
A; Sham + vehicle. B; MNX + vehicle. C; MNX + AR786 
Osteochondral channels (black arrow head) were found in the subchondral bone plate in 
sections from Sham + vehicle (A, D), MNX + vehicle (B, E) and MNX + AR786 group (C, 
F). CGRP-IR sensory nerves invading osteochondral ch nnels from bone marrow space 
(white arrow head) under areas of damaged cartilage ( st risk) in MNX + vehicle group (G, 
H). The increase in CGRP-IR nerves within osteochondral channels under areas of 
damaged cartilage (asterisk) was prevented in MNX + AR786 group (I, J). CGRP-IR 
sensory nerves (arrow) were found in bone marrow space (K). MNX; meniscal transection, 
CGRP-IR; calcitonin gene-related peptide-immunoreactive. Scale bars = 100 µm 
 
Figure 4: Percentage of osteochondral channels containing CGRP-IR sensory nerves 
and nerve density in bone marrow space from sham plus vehicle, MNX plus vehicle 
and MNX plus AR786 models. 
Lines represent medians and IQR. *p=0.02 versus Sham + vehicle and *p=0.03 versus 
MNX + AR786. Data were analysed using Kruskal-Wallis test followed by post hoc 
Dunn’s comparison. MNX; meniscal transection, CGRP; calcitonin gene-related 









Age 50 (47, 65) 86 (78, 89) 61 (58, 73) 
Gender (Male, %) 70 50 67 
Macroscopic chondropathy score (0-100) 20 (17, 26) 68 (62, 83) ***** 73 (66, 79) **** 
Total radiographic OA severity score (0-18) NA NA 12 (10.5 13) 
    Tibiofemoral JSN score (0-6) NA NA 5 (5, 5) 
    Medial tibiofemoral JSN score (0-3) NA NA 3 (3,3) 
    Osteophyte score (0-12) NA NA 7 (5.5, 8) 
    Medial tibial osteophyte score (0-3) NA NA 2 (1.5, 2) 
Total Mankin score (0-14) 6 (5, 8) 9 (6, 11) 11 (9, 12) * 
   Loss of cartilage surface integrity (0-6) 3 (2, 3) 5 (3, 6) *** 6 (4, 6) ** 
   Chondrocyte appearance (0-3) 2 (2, 3) 3 (3, 3) 3 (3, 3) 
   Loss of tidemark integrity (Yes, %) 45 70 70 
   Proteoglycan loss (0-4) 1 (1, 1) 2 (1, 2) 2 (2, 2) 
Subchondral bone marrow replacement 
(Yes, %) 
45 67 64 
Density of channels breaching tidemark 
(/mm) 
0.00 (0.00, 0.00) 0.03 (0, 0.10) 0.07 (0.00, 0.13) 
Total osteochondral channel density (/mm) 4.4 (3.9, 4.7) 3.7 (3.0, 5.0) 4.1 (3.3, 6.6) 
 
Table 1: Details of demographics, radiographic OA severity and OA pathology 
Data displayed as median (IQR). Total radiographic OA severity score is a summation of 
tibiofemoral joint space narrowing (JSN) and osteophyte scores. Tibiofemoral JSN score is a 
summation of medial and lateral tibiofemoral JSN scores. Osteophyte score is a summation of 
medial and lateral tibial and femoral osteophyte scores. Data were analysed using Kruskal-Wallis 
test followed by post hoc Dunn’s comparison. *p=0.01, **p=0.007, ***p=0.006, ****p=0.003, 
*****p=0.0002 versus non-arthritic control. JSN; joint space narrowing, NA = Not available. 
 
 SHAM + Vehicle MNX + Vehicle MNX + AR786 
Macroscopic chondropathy score 0 (0, 0.8) 3 (3, 3)** 3 (3, 4)**** 
Cartilage damage score (0-15) 0 (0, 0) 5 (3, 8) 6 (5, 10)* 
Osteophyte score (0-3) 0 (0, 0) 1 (0, 3) 1 (0, 2) 
Osteochondral channel density (/mm) 3.1 (2.9, 3.3) 2.5 (2.2, 3.6) 3.5 (2.5, 4.6) 
Subchondral bone marrow replacement (%) 0 50 66.7* 
Paw withdrawal threshold (g) 15 (11, 15) 6 (5, 6) *** , # 13 (10, 15) 
Weight-bearing asymmetry (%) 1.2 (0.1, 1.9) 25.2 (20.6, 27.4) ***, ## 1.5 (0.6, 3.8) 
 
Table 2: Histology and pain behavior 28 days after knee surgery in rats  
Data displayed as median (IQR) and 95 confidence interval (CI) for median. Data were analysed 
using Kruskal-Wallis test followed by post hoc Dunn’s comparison. *p=0.003, **p=0.002, 
***p=0.0001, ****p<0.0001 versus SHAM+Vehicle. #p=0.003, ##p=0.002 versus MNX + AR786. 
MNX; meniscal transection. Weight-bearing asymmetry is given as percent difference in 
distribution between hindlimbs.  
¥; Macroscopic chondropathy score, paw withdrawal thres old and weight-bearing asymmetry 
have been previously published8. 
 
Supplementary text 
Method of Zamboni23 
Samples were fixed using a solution of 2% (w/v) paraformaldehyde, 15% (v/v) picric acid in 
phosphate buffer (pH 7.3, 4°C) overnight, and then tra sferred to 15% (w/v) sucrose in phosphate 
buffered saline (4°C) solution for 5 days. 
 
Mankin scoring system26 
Cartilage surface integrity (0 [normal] to 6 [complete disorganisation]), tidemark integrity (0 
[intact] or 1 [crossed by vessels]), chondrocyte morph logy (0 [normal] to 3 [hypocellular]) and 
proteoglycan loss (0 [normal, no loss of Safranin-O stain] to 4 [complete loss of stain]).
 
Figure 1: Histopathologic features in cartilage and subchondral bone from humans 
 
 
Figure 2: Percentage of osteochondral channels containing CGRP-IR sensory 




Figure 3: Histopathologic features in cartilage and subchondral bone from rats 
 
Figure 4: Percentage of osteochondral channels containing CGRP-IR sensory 
nerves and nerve density in bone marrow space from sham plus vehicle, MNX plus 
vehicle and MNX plus AR786 models. 
 
